Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Ignite Planners LLC

Ignite Planners LLC lowered its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 9.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,395 shares of the medical research company’s stock after selling 675 shares during the quarter. Ignite Planners LLC’s holdings in Edwards Lifesciences were worth $577,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. Alliancebernstein L.P. boosted its stake in Edwards Lifesciences by 27.5% in the fourth quarter. Alliancebernstein L.P. now owns 21,874,280 shares of the medical research company’s stock valued at $1,632,040,000 after acquiring an additional 4,712,819 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Edwards Lifesciences by 3.8% in the 1st quarter. Wellington Management Group LLP now owns 15,850,055 shares of the medical research company’s stock valued at $1,311,275,000 after purchasing an additional 578,319 shares during the period. Moneta Group Investment Advisors LLC increased its position in Edwards Lifesciences by 104,971.3% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company’s stock worth $1,148,938,000 after buying an additional 15,384,593 shares during the period. Brown Advisory Inc. lifted its stake in Edwards Lifesciences by 0.8% in the fourth quarter. Brown Advisory Inc. now owns 14,341,102 shares of the medical research company’s stock valued at $1,069,990,000 after buying an additional 115,268 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Edwards Lifesciences by 0.6% in the first quarter. Geode Capital Management LLC now owns 12,214,619 shares of the medical research company’s stock valued at $1,008,114,000 after acquiring an additional 78,376 shares during the period. Hedge funds and other institutional investors own 79.25% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on EW shares. Truist Financial upped their price target on shares of Edwards Lifesciences from $101.00 to $105.00 in a research report on Wednesday, July 19th. Mizuho boosted their price target on Edwards Lifesciences from $95.00 to $102.00 in a research report on Monday, July 17th. TheStreet cut Edwards Lifesciences from a “b-” rating to a “c+” rating in a research report on Wednesday, August 9th. Citigroup boosted their target price on Edwards Lifesciences from $101.00 to $110.00 in a report on Monday, July 10th. Finally, Jefferies Financial Group increased their price target on Edwards Lifesciences from $103.00 to $107.00 and gave the stock a “buy” rating in a report on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $92.42.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 4,500 shares of the stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $73.71, for a total transaction of $331,695.00. Following the sale, the vice president now owns 39,503 shares of the company’s stock, valued at $2,911,766.13. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, Director Michael A. Mussallem sold 29,350 shares of the company’s stock in a transaction dated Wednesday, July 5th. The shares were sold at an average price of $90.78, for a total transaction of $2,664,393.00. Following the completion of the transaction, the director now owns 54,252 shares of the company’s stock, valued at approximately $4,924,996.56. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 4,500 shares of the company’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $73.71, for a total transaction of $331,695.00. Following the transaction, the vice president now directly owns 39,503 shares of the company’s stock, valued at approximately $2,911,766.13. The disclosure for this sale can be found here. Insiders sold a total of 174,359 shares of company stock valued at $14,301,522 over the last three months. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock traded down $0.31 during trading hours on Monday, hitting $72.89. The stock had a trading volume of 2,327,115 shares, compared to its average volume of 3,160,659. The stock has a market capitalization of $44.31 billion, a price-to-earnings ratio of 32.01, a PEG ratio of 4.00 and a beta of 1.03. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.15 and a quick ratio of 2.30. Edwards Lifesciences Co. has a 1-year low of $67.13 and a 1-year high of $94.87. The stock’s fifty day moving average is $81.38 and its two-hundred day moving average is $83.98.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Wednesday, July 26th. The medical research company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.01. Edwards Lifesciences had a net margin of 24.56% and a return on equity of 25.43%. The firm had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.51 billion. During the same period last year, the firm posted $0.63 EPS. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. As a group, analysts predict that Edwards Lifesciences Co. will post 2.55 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.